IXICO PLC

IXI
Delayed Quote. Delayed  - 01/20 11:35:08 am
89.5GBX --.--%

IXICO : to Present at Alzheimer's Disease Congress

12/02/2019 | 02:08am
RNS Reach Story
Go to market news section
IXICO plc - IXI
IXICO to Present at Alzheimer's Disease Congress
Released 07:00 02-Dec-2019



RNS Number : 2147V
IXICO plc
02 December 2019

2nd December 2019

IXICO plc

('IXICO' or the 'Company')

IXICO to Present Abstracts at Upcoming Clinical Trials on Alzheimer's Disease Congress

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience clinical drug development, today announces that it is scheduled to attend and present scientific posters at the 2019 Clinical Trials on Alzheimer's Disease (CTAD) Congress held from 4th-7th December 2019 in San Diego, California, USA.

CTAD Congress 2019

4th - 7th December 2019, Hilton Bayfront, San Diego, USA

IXICO will present three posters during break-out sessions in the Indigo Foyer on Thursday, 5th December. Details of the posters are as follows:

'Classifying cognitively healthy subjects from mild cognitive impaired and Alzheimer's disease patients using Tau-PET: the role of spatial resolution and PET pre-processing'

Given the connection between Alzheimer's disease and the spatial bio-distribution of misfolded phosphorylated Tau protein, this research investigates how the uptake of Tau-PET scans differs in patients affected with different degrees of cognitive impairment.

Poster authors:

Richard Joules1, Alessandro Palombit1, Richard Manber1, Richard Parker1, Robin Wolz1,2

Affiliations: 1- IXICO Plc, London, UK, 2- Imperial College London, UK

'A fully automatic pipeline for estimation of regional brain volume change using Jacobian Integration'

The poster highlights the methods used for estimating regional brain volume change in Alzheimer's disease patients, by validating the fully automatic Jacobian Integration pipeline using LEAP technology against the commonly accepted standard Boundary Shift Integration (BSI) method when estimating volume change in the lateral ventricles of an Alzheimer's disease cohort.

Poster authors:

Richard Joules1, Robin Wolz1,2, Richard Parker1

Affiliations: 1- IXICO Plc, London, UK, 2- Imperial College London, UK

'A pipeline for automated diffusion MRI analysis: overview and application to the study of Alzheimer's disease'

This research introduces and validates a pipeline for the analysis of diffusion MRI brain scan data that is fully integrated into IXICO's trial management software, TrialTracker™: a web-based tool for data upload, storage, data analysis and quality assessment of processed data. The pipeline is applied to a cohort of older adults with and without Alzheimer's disease.

Poster authors:

Richard Joules1, Robin Wolz1,2, Richard Parker1

Affiliations: 1- IXICO Plc, London, UK, 2- Imperial College London, UK

Alison Howie, Chief Product Officer of IXICO,commented:'We are delighted to be presenting three abstracts at this year's CTAD Congress, demonstrating IXICO's expertise in advancing data analytics to deliver intelligent insights which are vital in ensuring the successful progression of clinical trials. IXICO's key mission is the development of data analytics to speed the advancement of effective treatments for neurodegenerative diseases, like Alzheimer's disease, that tragically affect so many patients worldwide.'

For further information please contact:

IXICO plc

+44 (0) 20 3763 7498

Alison Howie, Chief Product Officer




Optimum Strategic Communications

+44 (0) 203 950 9144

Mary Clark / Supriya Mathur / Manel Mateus


IXICO@optimumcomms.com


About IXICO

IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and rare disease.

Our goal is to be a leading proponent in the use of Artificial Intelligence (AI) in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience and rare disease, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.

More information is available on www.IXICO.com

About CTAD Congress 2019

The development of the next generation of Alzheimer's disease treatments is among the most important health needs worldwide but presents huge challenges. The goal of the meeting is to bring together today's worldwide leaders in the treatment of Alzheimer's disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer's disease treatments.

Clinical trial teams from worldwide centres report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk from Alzheimer's disease, to predict progression, and assess the effectiveness of new treatments.https://www.ctad-alzheimer.com/


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NRAMMMZMVLVGLZM
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.
©2014London Stock Exchange plc. All rights reserved



IXICO to Present at Alzheimer's Disease Congress - RNS

Disclaimer

IXICO plc published this content on 02 December 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 December 2019 07:07:16 UTC

© Publicnow 2021
Copier lien
All news about IXICO PLC
12/24
12/08
12/02
12/02
11/27